Savara Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
123
- Stock Symbol
-
SVRA
- Investments
-
3
- Share Price
-
$4.63
- (As of Friday Closing)
Savara General Information
Description
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Contact Information
Website
www.savarapharma.comCorporate Office
- The Tannery Building, 19 West College Avenue
- Suite 200
- Yardley, PA 19067
- United States
Corporate Office
- The Tannery Building, 19 West College Avenue
- Suite 200
- Yardley, PA 19067
- United States
Savara Stock Performance
As of 13-Nov-2026, Savara’s stock price is $4.63. Its current market cap is $1.02B with 221M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.63 | $4.72 | $4.13 - $7.00 | $1.02B | 221M | 2.28M | -$0.60 |
Savara Financials Summary
As of 30-Sep-2026, Savara has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 917,547 | 1,132,355 | 334,138 | 494,272 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (156,215) | (122,912) | (102,218) | (59,057) |
| Net Income | (152,737) | (118,837) | (95,881) | (54,698) |
| Total Assets | 155,933 | 253,436 | 212,879 | 177,564 |
| Total Debt | 30,363 | 29,914 | 26,735 | 26,491 |
Savara Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Savara Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Savara Comparisons
Industry
Financing
Details
Savara Competitors (21)
One of Savara’s 21 competitors is Xeris Biopharma Holdings, a Formerly VC-backed company based in Chicago, IL.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings | Formerly VC-backed | Chicago, IL | ||||
| Zealand Pharma | Formerly VC-backed | Soborg, Denmark | ||||
| Kyntra Bio | Formerly VC-backed | San Francisco, CA | ||||
| Verona Pharma | Corporate Backed or Acquired | London, United Kingdom | ||||
| FibroGen (China) | Corporate Backed or Acquired | Beijing, China |
Savara Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Savara Patents
Savara Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023240286-A1 | Drug-device combination | Active | 21-Mar-2022 | ||
| AU-2023240286-B2 | Drug-device combination | Active | 21-Mar-2022 | ||
| EP-4249022-A1 | Drug-device combination | Inactive | 21-Mar-2022 | ||
| EP-4496611-A1 | Drug-device combination | Active | 21-Mar-2022 | ||
| US-20260048206-A1 | Drug-device combination | Pending | 21-Mar-2022 | A61M11/005 |
Savara Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Savara Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Savara Investments & Acquisitions (3)
Savara’s most recent deal was a Corporate Asset Purchase with Cardeas Pharma (Inhaled Antibiotic Rights). The deal was made on 25-Jul-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Cardeas Pharma (Inhaled Antibiotic Rights) | 25-Jul-2018 | Corporate Asset Purchase | Buildings and Property | ||
| Mast Therapeutics | 27-Apr-2017 | Merger/Acquisition | Drug Discovery | ||
| Serendex Pharmaceuticals | 15-Jul-2016 | Merger/Acquisition | Buildings and Property |
Savara ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
36.45 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Savara Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Aravas | Austin, TX | 2007 |
Savara FAQs
-
When was Savara founded?
Savara was founded in 2007.
-
Where is Savara headquartered?
Savara is headquartered in Yardley, PA.
-
What is the size of Savara?
Savara has 123 total employees.
-
What industry is Savara in?
Savara’s primary industry is Drug Discovery.
-
Is Savara a private or public company?
Savara is a Public company.
-
What is Savara’s stock symbol?
The ticker symbol for Savara is SVRA.
-
What is the current stock price of Savara?
As of 13-Nov-2026 the stock price of Savara is $4.63.
-
What is the current market cap of Savara?
The current market capitalization of Savara is $1.02B.
-
Who are Savara’s competitors?
Xeris Biopharma Holdings, Zealand Pharma, Kyntra Bio, Verona Pharma, and FibroGen (China) are some of the 21 competitors of Savara.
-
What is Savara’s annual earnings per share (EPS)?
Savara’s EPS for 12 months was -$0.60.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
